Immune Therapeutics Inc. (IMUN) a specialty pharmaceutical company, committed to the commercialization of our patented therapies focused on the activation and re-balancing of the body’s immune system.
Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.
IMUN CAR-T Technology
Immune Therapeutics Inc. recently acquired the Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and therapeeutic clinical data from Super-T Cell Cancer Company (“STCC”) a newly formed corporation
Met-enkephalin, some times referred to as Opioid Growth Factor (OGF) have been studied by a number of scientists but the most published of these are Dr. Ian Zagon and his team from Pennsylvania State Medical Center at Hershey extensively in relationship to growth – especially in cancer and Dr. Nicholas Plotnikoff in conjunction with. Bihari and Dr. Ronald Herberman and Robert Good in the treatment of HIV/AIDS and cancer. Much of this research has been carried out in the USA, Belgium, Croatia and Germany.
Low Dose Naltrexone
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial.
2431 Aloma Ave #124 Winter Park, FL 3279